Ko DT, Khera R, Lau G, Qiu F, Wang Y, Austin PC, Koh M, Lin Z, Lee DS, Wijeysundera HC, Krumholz HM. Readmission and mortality after hospitalization for myocardial infarction and heart failure. J Am Coll Cardiol. 2020;75(7):736–46. https://doi.org/10.1016/j.jacc.2019.12.026.

Article  PubMed  Google Scholar 

Steen DL, Khan I, Andrade K, et al. Event rates and risk factors for recurrent cardiovascular events and mortality in a contemporary post acute coronary syndrome population representing 239,234 patients during 2005 to 2018 in the United States. J Am Heart Assoc. 2022;11(9): e022198.

Article  PubMed  PubMed Central  Google Scholar 

Rosenblit PD. Extreme atherosclerotic cardiovascular disease (ASCVD) risk recognition. Curr Diab Rep. 2019;19(8):61.

Article  PubMed  Google Scholar 

2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Atherosclerosis. 2019;290:140–205.

Dyrbuś K, Gąsior M, Penson PE, et al. Extreme cardiovascular risk-do we need a new risk category? Eur Heart J. 2022;43(19):1784–6.

Article  PubMed  Google Scholar 

Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Ketchum SB, Doyle RT Jr, Juliano RA, Jiao L, Granowitz C, Tardif JC, Ballantyne CM, REDUCE-IT Investigators. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. N Engl J Med. 2019;380(1):11–22. https://doi.org/10.1056/NEJMoa1812792.

Article  CAS  PubMed  Google Scholar 

Giugliano RP, Pedersen TR, Park JG, De Ferrari GM, Gaciong ZA, Ceska R, Toth K, Gouni-Berthold I, Lopez-Miranda J, Schiele F, Mach F, Ott BR, Kanevsky E, Pineda AL, Somaratne R, Wasserman SM, Keech AC, Sever PS, Sabatine MS, FOURIER Investigators. Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial. Lancet. 2017;390(10106):1962–71. https://doi.org/10.1016/S0140-6736(17)32290-0.

Article  CAS  PubMed  Google Scholar 

Davies MJ, Drexel H, Jornayvaz FR, Pataky Z, Seferović PM, Wanner C. Cardiovascular outcomes trials: a paradigm shift in the current management of type 2 diabetes. Cardiovasc Diabetol. 2022;21(1):144. https://doi.org/10.1186/s12933-022-01575-9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Perera KS, Ng KKH, Nayar S, Catanese L, Dyal L, Sharma M, Connolly SJ, Yusuf S, Bosch J, Eikelboom JW, Hart RG. Association between low-dose rivaroxaban with or without aspirin and ischemic stroke subtypes: a secondary analysis of the COMPASS trial. JAMA Neurol. 2020;77(1):43–8. https://doi.org/10.1001/jamaneurol.2019.2984.

Article  PubMed  Google Scholar 

Maloberti A, Fabbri S, Colombo V, Gualini E, Monticelli M, Daus F, Busti A, Galasso M, De Censi L, Algeri M, Merlini PA, Giannattasio C. Lipoprotein(a): cardiovascular disease, aortic stenosis and new therapeutic option. Int J Mol Sci. 2022;24(1):170. https://doi.org/10.3390/ijms24010170.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhu L, Zheng J, Gao B, et al. The correlation between lipoprotein(a) elevations and the risk of recurrent cardiovascular events in CAD patients with different LDL-C levels. BMC Cardiovasc Disord. 2022;22(1):171.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Maloberti A, Biolcati M, Ruzzenenti G, Giani V, Leidi F, Monticelli M, Algeri M, Scarpellini S, Nava S, Soriano F, Oreglia J, Sacco A, Morici N, Oliva F, Piani F, Borghi C, Giannattasio C. The role of uric acid in acute and chronic coronary syndromes. J Clin Med. 2021;10(20):4750. https://doi.org/10.3390/jcm10204750.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Maloberti A, Giannattasio C, Bombelli M, Desideri G, Cicero AFG, Muiesan ML, Rosei EA, Salvetti M, Ungar A, Rivasi G, et al. Hyperuricemia and risk of cardiovascular outcomes: the experience of the URRAH (Uric Acid Right for Heart Health) project. High Blood Press Cardiovasc Prev. 2020;27:121–8.

Article  PubMed  Google Scholar 

Hoogeveen RC, Ballantyne CM. Residual cardiovascular risk at low LDL: remnants, lipoprotein(a), and inflammation. Clin Chem. 2021;67(1):143–53. https://doi.org/10.1093/clinchem/hvaa252.

Article  PubMed  Google Scholar 

Sethwala AM, Goh I, Amerena JV. Combating inflammation in cardiovascular disease. Heart Lung Circ. 2021;30(2):197–206. https://doi.org/10.1016/j.hlc.2020.09.003. (Epub 2020 Oct 8).

Article  PubMed  Google Scholar 

Conte M, Rozza F, Fucile I, D’Avino G, Sorvillo G, De Luca N, Mancusi C. Low awareness of cardiovascular risk factor among patients admitted in cardiac rehabilitation unit. High Blood Press Cardiovasc Prev. 2021;28(3):321–4.

Article  PubMed  Google Scholar 

Bianchi S, Maloberti A, Peretti A, Garatti L, Palazzini M, Occhi L, Bassi I, Sioli S, Biolcati M, Giani V, Monticelli M, Leidi F, Ruzzenenti G, Beretta G, Giannattasio C, Riccobono S. Determinants of functional improvement after cardiac rehabilitation in acute coronary syndrome. High Blood Press Cardiovasc Prev. 2021;28(6):579–87. https://doi.org/10.1007/s40292-021-00473-7. (Epub 2021 Sep 13).

Article  PubMed  PubMed Central  Google Scholar 

Greco A, Brugnera A, Adorni R, D’Addario M, Fattirolli F, Franzelli C, Giannattasio C, Maloberti A, Zanatta F, Steca P. Protein intake and physical activity in newly diagnosed patients with acute coronary syndrome: a 5-year longitudinal study. Nutrients. 2021;13(2):634.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chen HY, Saczynski JS, Lapane KL, Kiefe CI, Goldberg RJ. Adherence to evidence-based secondary prevention pharmacotherapy in patients after an acute coronary syndrome: a systematic review. Heart Lung. 2015;44(4):299–308.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Krumholz HM, Anderson JL, Brooks NH, et al. ACC/AHA clinical performance measures for adults with ST-elevation and non-ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on performance measures (Writing Committee to develop performance measures on ST-elevation and non-ST-elevation myocardial infarction). J Am Coll Cardiol. 2006;47(1):236–65.

Article  PubMed  Google Scholar 

Doll JA, Hellkamp A, Thomas L, et al. Participation in cardiac rehabilitation, readmissions, and death after acute myocardial infarction. Am J Med. 2014;127(6):538–46.

Article  Google Scholar 

Brown TM, Hernandez AF, Bittner V, Cannon CP, Ellrodt G, Liang L, Peterson ED, Piña IL, Safford MM, Fonarow GC, American Heart Association Get With The Guidelines Investigators. Predictors of cardiac rehabilitation referral in coronary artery disease patients. Findings from the American Heart Association’s get with the Guidelines Program. J Am Coll Cardiol. 2009;54(6):515–21.

Article  PubMed  PubMed Central  Google Scholar 

Maloberti A, Bombelli M, Vallerio P, Milani M, Cartella I, Tavecchia G, Tognola C, Grasso E, Sun J, De Chiara B, Riccobono S, Grassi G, Giannattasio C. Metabolic syndrome is related to vascular structural alterations but not to functional ones both in hypertensives and healthy subjects. Nutr Metab Cardiovasc Dis. 2021;31(4):1044–52. https://doi.org/10.1016/j.numecd.2020.11.011. (Epub 2020 Nov 20).

Article  PubMed  Google Scholar 

Tomlinson JE, McLean JW, Lawn RM. Rhesus Monkey Apolipoprotein(a). Sequence, evolution, and sites of synthesis. J Biol Chem. 1989;264:5957–65.

Article  CAS  PubMed  Google Scholar 

The CARDIoGRAMplusC4D Consortium, Deloukas P, Kanoni S, Willenborg C, Farrall M, Assimes TL, Thompson JR, Ingelsson E, Saleheen D, Erdmann J, et al. Large-scale association analysis identifies new risk loci for coronary artery disease. Nat Genet. 2013;45:25–33.

Article  Google Scholar 

Clarke R, Peden JF, Hopewell JC, Kyriakou T, Goel A, Heath S, Parish S, Barlera S, Franzosi MG, Rust S, et al. Genetic variants associated with Lp(a) lipoprotein level and coronary disease. N Engl J Med. 2009;361:2518–28.

Article  CAS  PubMed  Google Scholar 

Berman AN, Blankstein R. Current and future role of lipoprotein(a) in preventive cardiology. Curr Opin Cardiol. 2019;34:514–8.

Article  PubMed  Google Scholar 

Pavanello C, Pirazzi C, Bjorkman K, Sandstedt J, Tarlarini C, Mosca L, Romeo S, Calabresi L, Mancina RM. Individuals with familial hypercholesterolemia and cardiovascular events have higher circulating Lp(a) levels. J Clin Lipidol. 2019;13:778-787.e6.

Article  PubMed  Google Scholar 

Sun L, Li Z, Zhang H, Ma A, Liao Y, Wang D, Zhao B, Zhu Z, Zhao J, Zhang Z, et al. Pentanucleotide TTTTA repeat polymorphism of apolipoprotein(a) gene and plasma lipoprotein(a) are associated with ischemic and hemorrhagic stroke in Chinese: a multicenter case–control study in China. Stroke. 2003;34:1617–22.

Article  CAS  PubMed  Google Scholar 

Dieplinger B, Lingenhel A, Baumgartner N, Poelz W, Dieplinger H, Haltmayer M, Kronenberg F, Mueller T. Increased serum lipoprotein(a) concentrations and low molecular weight phenotypes of apolipoprotein(a) are associated with symptomatic peripheral arterial disease. Clin Chem. 2007;53:1298–305.

Article  CAS  PubMed  Google Scholar 

Verwer MC, Waissi F, Mekke JM, Dekker M, Stroes ES, de Borst GJ, Kroon J, Hazenberg CE, de Kleijn DP. High lipoprotein(a) is associated with major adverse limb events after femoral artery endarterectomy. Atherosclerosis. 2022;349:196–203.

Article  CAS  PubMed  Google Scholar 

Sakata K, Kumakura H, Funada R, Matsuo Y, Nakashima K, Iwasaki T, Ichikawa S. Lipoprotein(a) is a promising residual risk factor for long-term clinical prognosis in peripheral arterial disease. Ann Vasc Dis. 2022;15:186–92.

Article  PubMed  PubMed Central  Google Scholar 

Yoon YH, Ahn JM, Kang DY, Lee PH, Kang SJ, Park DW, Lee SW, Kim YH, Han KH, Lee CW, Park SW, Park SJ. Association of lipoprotein(a) with recurrent ischemic events following percutaneous coronary intervention. JACC Cardiovasc Interv. 2021;14(18):2059–68.

Article  PubMed  Google Scholar 

Silverio A, Cancro FP, Di Maio M, Bellino M, Esposito L, Centore M, Carrizzo A, Di Pietro P, Borrelli A, De Luca G, Vecchione C, Galasso G. Lipoprotein(a) levels and risk of adverse events after myocardial infarction in patients with and without diabetes. J Thromb Thrombolysis. 2022;54(3):382–92.

Article  CAS